Methamphetamine Abuse Clinical Trial
Official title:
Preliminary Efficacy of a Digital Therapeutics Smartphone Application for Methamphetamine Use Disorder
NCT number | NCT05550493 |
Other study ID # | Feidao |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2021 |
Est. completion date | May 1, 2022 |
Verified date | November 2022 |
Source | Adai Technology (Beijing) Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
One hundred participants were recruited and randomized into a digital therapeutics (DTx) group (n=52) and a treatment as usual (TAU) group (n=48). The DTx group used a smartphone application to deliver cognitive behavioral therapy, approach bias modification, cognitive training, and contingency management for eight weeks. The TAU group received counseling from social workers and psychoterapists. Cue-induced craving, cognitive functions, PHQ-9, and GAD-7 were measured at baseline and post-intervention.
Status | Completed |
Enrollment | 100 |
Est. completion date | May 1, 2022 |
Est. primary completion date | March 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - currently undergoing community-based rehabilitation were recruited voluntarily from four community - meeting Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for methamphetamine dependence. Exclusion Criteria: - could not fluently operate an Android or an iOS smartphone - having mental health conditions other than MUD |
Country | Name | City | State |
---|---|---|---|
China | Huangshui Township Municipal Government | Chengdu | Sichuang |
Lead Sponsor | Collaborator |
---|---|
Adai Technology (Beijing) Co., Ltd. | Huangshui Township Municipal Government, Shuangliu District, Chengdu, Sichuang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cue induced craving for methamphetamine | The cue-induced craving was assessed by showing the participants images related to methamphetamine (methamphetamine crystals, powders, and paraphernalia) on a smartphone and asking them to rate their cravings on a 0-10 visual analog scale (0 being least craved and 10 being most craved). | baseline, pre-intervention | |
Primary | Cue induced craving for methamphetamine | The cue-induced craving was assessed by showing the participants images related to methamphetamine (methamphetamine crystals, powders, and paraphernalia) on a smartphone and asking them to rate their cravings on a 0-10 visual analog scale (0 being least craved and 10 being most craved). | immediately after the intervetion | |
Primary | Cognitive Function Score | We use the Meaningless Figure Recognition Test (MFRT) to assess the cognitive function score. This test has eight blocks, and each block has two phases. In the first phase, the participant is presented with a series of meaningless figures one by one for three seconds. The participants were asked to memorize these figures. In the second phase, the previously presented meaningless figures and the same number of the novel meaningless figures are presented on one screen in random order. The participants were asked to recall their memory and click all the previously presented figures within 15 seconds. The correct rate of clicks is used for measuring the cognitive function scores. | baseline, pre-intervention | |
Primary | Cognitive Function Score | We use the Meaningless Figure Recognition Test (MFRT) to assess the cognitive function score. This test has eight blocks, and each block has two phases. In the first phase, the participant is presented with a series of meaningless figures one by one for three seconds. The participants were asked to memorize these figures. In the second phase, the previously presented meaningless figures and the same number of the novel meaningless figures are presented on one screen in random order. The participants were asked to recall their memory and click all the previously presented figures within 15 seconds. The correct rate of clicks is used for measuring the cognitive function scores. | immediately after the intervetion | |
Secondary | PHQ-9 | Patient Health Questionaire-9 administered on a smartphone | baseline, pre-intervention | |
Secondary | PHQ-9 | Patient Health Questionaire-9 administered on a smartphone | immediately after the intervetion | |
Secondary | GAD-7 | Generalized Anxiety Disorder 7-item administered on a smartphone | baseline, pre-intervention | |
Secondary | GAD-7 | Generalized Anxiety Disorder 7-item administered on a smartphone | immediately after the intervetion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Completed |
NCT03226223 -
Pharmacogenetics of Naltrexone for Stimulant Abuse
|
Phase 2 | |
Not yet recruiting |
NCT05593796 -
Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder
|
N/A | |
Completed |
NCT02907853 -
Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa
|
N/A | |
Recruiting |
NCT04616625 -
Cardiovascular Effects of Prenatal Methamphetamine Exposure
|
||
Completed |
NCT04061941 -
Change in Cognitive Function in Stimulant Users
|
||
Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT05700994 -
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
|
N/A | |
Completed |
NCT04109014 -
FASTLANE II: Reducing Sex, Drug, and Mental Health Risk
|
N/A | |
Completed |
NCT03336866 -
Study of Antibody for Methamphetamine Outpatient Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT01822132 -
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
|
N/A | |
Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
Not yet recruiting |
NCT06233799 -
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
|
Phase 3 | |
Recruiting |
NCT05521854 -
Contingency Management for Drug Use: Does Age Matter?
|
N/A | |
Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
Not yet recruiting |
NCT05334914 -
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
|
N/A |